On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair ... with the scientific team ...

So far this year, Eli Lilly (NYSE ... During its third-quarter earnings call a few weeks ago, Viking's management revealed ...

In all likelihood, when the management team at Eli Lilly and Company announces financial results for the third quarter of the 2024 fiscal year, that growth will be considered rather significant.

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q3 2024 earnings call. [Operator ...

Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.

In addition to top-line figures that missed Wall Street expectations, management ... team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Despite the above, there are still a couple of silver linings that provide more than enough reason to be bullish about this stock.

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily outperforming both the S&P 500 and Nasdaq Composite indexes. Much of the ...

In addition to top-line figures that missed Wall Street expectations, management lowered its earnings outlook. If there's one thing the stock market hates, it's unpredictability. Eli Lilly shares were ...